LOUISVILLE, Colo., Aug. 9 /PRNewswire/ -- GlobeImmune, Inc., today announced the appointment of Jules Harris, M.D. to the GlobeImmune Scientific Advisory Board. Dr. Harris joins existing advisors Teresa Brentnall, M.D., Paul Bunn, M.D., Dr. Francis Chisari, M.D., Charles Dinarello, M.D., Edgar Engleman, M.D., Carl June, M.D., Edward Mocarski, Ph.D., Robert Peach, Ph.D., Robert (Chip) Schooley, M.D., Alan Venook, M.D., and Bruce Walker, M.D.
Dr. Harris is presently a Visiting Professor of Medicine at the Arizona Cancer Center, University of Arizona in Tucson. He is also Emeritus Presidential Professor of Medicine at Rush University Medical Center, Chicago, IL, where he had previously served as the Director of the Section of Medical Oncology of the University and Director of the University’s Cancer Center. Dr. Harris has also served as the Associate Director of Clinical Trials of the Illinois Cancer Council, the Comprehensive Cancer Center for the State of Illinois. He has been the Chairman of the Immunological Devices Panel of the Food and Drug Administration. He has been a member of the American Society of Clinical Oncology Tumor Marker Advisory Panel. Recently, he has held an appointment as a Scientific Reviewer, Scientific Peer Review and Special Program of Research Excellence in Breast Cancer for the Department of Defense. Dr. Harris is also a member of the Pancreatic Cancer Research Team (PCRT), Phoenix, AZ.
Dr. Donald Bellgrau, Chairman of GlobeImmune’s Scientific Advisory Board and Company Founder commented, “We are delighted to welcome Dr. Harris to the SAB and to have the benefit of his expertise in pancreas cancer and clinical trial design as well as his deep experience in cancer immunology. We look forward to working closely with him on the development of our oncology programs.”
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development, and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens(TM) for the treatment of cancer and infectious diseases. The Company’s lead product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection, is currently in a placebo-controlled, Phase 1b human clinical trial. GI-4000, a Tarmogen for the treatment of various Ras-mediated cancers, is in a randomized, placebo-controlled, multi-center Phase 2 trial for the treatment of patients with early-stage pancreas cancer.
About Tarmogens
Tarmogens are whole, heat-killed recombinant yeast that are genetically modified to express one or more disease-specific protein antigens. Tarmogens actively bind to several receptors on antigen-presenting cells, including Toll-like receptors, and are avidly taken up by these cells that activate the immune system, stimulating an immune response to kill diseased cells. For additional information, please visit the company’s website at www.globeimmune.com.
GlobeImmune, Inc.
CONTACT: Kirk Christoffersen, Senior Director, Corporate Development ofGlobeImmune, Inc., +1-303-625-2700, information@globeimmune.com
Web site: http://www.globeimmune.com/
